Skip to main content
CLYM
NASDAQ Life Sciences

Major Investor RA Capital Boosts Stake to 33% in Climb Bio via $20M Private Placement at Premium

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$8.99
Mkt Cap
$419.408M
52W Low
$1.13
52W High
$10.1
52W Position info
696% above low
Off High info
11% below high
Rel. Volume info
2.0× avg
Market data snapshot near publication time

CLYM has more than doubled off its 52-week low of $1.13 on elevated volume (2.0× avg).

Summary

RA Capital Management increased its beneficial ownership in Climb Bio to 33.0% by investing $20.0 million in pre-funded warrants through a private placement priced at a premium to the current market.


Key Events · Ownership and Investor Activity · CLYM

  • Major Investor Increases Stake

    RA Capital Management, L.P. and its affiliates now beneficially own 22,631,401 shares, representing 33.0% of Climb Bio's common stock.

  • $20 Million Investment in Private Placement

    RA Capital purchased 2,106,000 pre-funded warrants for $20,006,789.40 in the private placement that closed on April 29, 2026.

  • Premium Pricing Signals Confidence

    The pre-funded warrants were acquired at a price of $9.4999 each, effectively $9.50 per share, which is a premium compared to the current market price of $8.9896.

  • Beneficial Ownership Blocker

    The pre-funded warrants include a provision preventing exercise if it would result in RA Capital's beneficial ownership exceeding 33.0% of the common stock.


Analysis · CLYM · Life Sciences

RA Capital Management, a significant institutional investor, has substantially increased its stake in Climb Bio, Inc. to 33.0% of outstanding common stock through a $20.0 million purchase of pre-funded warrants in the recently closed private placement. This investment, made at a price of $9.4999 per warrant (effectively $9.50 per share), which is a premium to the current market price of $8.9896, signals strong conviction from a key investor. The private placement, which raised $110 million for Climb Bio, provides crucial capital and this filing highlights a major investor's confidence in the company's future.

At the time of this filing, CLYM was trading at $8.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $419.4M. The 52-week trading range was $1.13 to $10.10. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CLYM - Latest Insights

CLYM
Jul 07, 2026, 4:41 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $13.65
Real-time Price: $12.92 info
Change: -$0.7304 (-5%) info
Market Cap: $703.763M info
CLYM
Jun 12, 2026, 4:36 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.44
Real-time Price: $12.92 info
Change: +$1.48 (+13%) info
Market Cap: $703.763M info
CLYM
Jun 12, 2026, 4:22 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $11.44
Real-time Price: $12.92 info
Change: +$1.48 (+13%) info
Market Cap: $703.763M info
CLYM
Jun 11, 2026, 7:23 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $10.91
Real-time Price: $12.92 info
Change: +$2.01 (+18%) info
Market Cap: $703.763M info
CLYM
Jun 11, 2026, 7:12 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.16
Real-time Price: $12.92 info
Change: +$1.76 (+16%) info
Market Cap: $703.763M info